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Abstract 15 
Organic micropollutants (OMPs) comprise a wide group of substances highly consumed 16 
in modern societies. There has been a growing social and scientific interest on OMPs in 17 
wastewaters in the 21st century. This research paper has identified the evolution of the 18 
research trends in the period 2001-2017 on OMPs fate during secondary wastewater 19 
treatment. These trends have moved from a global perspective on the occurrence of OMPs 20 
in wastewaters to more specific research focussed on understanding their behaviour 21 
during advanced treatment processes. Based on a bibliometric analysis carried out using 22 
one of the leading scientific databases, pharmaceuticals have been identified as the main 23 
group of OMPs. An increasing number of publications have been released on the fate of 24 
pharmaceuticals in wastewater with a growing number of countries involved: from 38 25 
publications belonging to 14 countries in first 5-year period analysed (2001-2005) up to 26 
138 from 42 countries only in the last two years (2016-2017). The main operational 27 
conditions in wastewater treatment plants influencing the removal of OMPs, as well as 28 
the mechanisms involved depending on the physico-chemical characteristics of the 29 
substances are reviewed. The paper also considers the role of microbial populations, as 30 
well as technological and operational features in OMPs abatement. Finally, a specific 31 
section is dedicated to the metabolic and cometabolic biotransformations of some OMPs 32 
taking place under heterotrophic, nitrifying and anaerobic conditions, a more novel 33 
research trend explored more recently.     34 
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1. Introduction 39 
The abatement of “emerging pollutants” is becoming a specific target in the conception 40 
of modern wastewater treatment schemes. In most cases the term used should be 41 
“pollutants of emerging concern”, since what is really new is the information recently 42 
obtained with the modern powerful analytical techniques which allow measuring 43 
concentrations of almost every compound consumed by our society at extremely low 44 
concentrations. Most of these pollutants are characterized by their occurrence at trace 45 
level, being consequently also referred to as micropollutants. Most of them have an  46 
organic nature, consequently called organic micropollutants (OMPs). 47 
OMPs comprise a wide group of substances largely consumed in modern societies (Omil 48 
et al., 2010), including pharmaceuticals, endocrine disruptors (EDCs), personal care 49 
products (PCPs), biocides, brominated flame retardants (BFRs), pesticides and linear 50 
alkylbenzene sulphonates (LAS). In general, the production of these substances has been 51 
increasing during the last years even though the population trend in many developed 52 
countries is hardly stable or declining, which constitutes an indication of the progressive 53 
higher consumption per capita of pharmaceuticals, hormones, other therapeutic 54 
substances, cosmetics, etc. The aging of society plays a key role in such trend, but also 55 
other changes in social habits are relevant, as for example the access to contraception, 56 
which supposes an increasing consumption of the hormone 17 -ethinylestradiol (EE2, 57 
the active ingredient of the contraceptive pill). The extensive use of antibiotics, new 58 
antiviral drugs or disinfectants is another example of the wide distribution of these 59 
substances in our society (Van der Aa et al., 2011).  60 
Pharmacokinetics is the study of the time course of drug absorption, distribution, 61 
metabolism, and excretion from the body (usually into the water cycle). It is a key issue 62 
to estimate the concentration of pharmaceuticals and endocrine disruptors in wastewaters, 63 
together with their consumption and disposal patterns (Ortiz de Garcia et al., 2013; Besse 64 
et al., 2008; Kolpin et al., 2004). In fact, compounds with a low excretion rate, such as 65 
ibuprofen (IBP), diclofenac (DCF) or sulfamethoxazole (SMX), are usually present at 66 
noticeable concentrations in wastewaters due to their massive use (Kolpin et al., 2004). 67 
Other important factors to be considered are the diurnal occurrence patterns, which are 68 
correlated with the daily drug administration (Plósz et al., 2010) and with the climate 69 
conditions. In this sense, increases in the concentration of pharmaceuticals in wastewater 70 
were observed under dry weather conditions in combined sewer systems (Kasprzyk-71 
Hordern et al., 2009). A seasonal influence on the concentrations of several 72 
pharmaceuticals, such as IBP and ketoprofen (KET) has been reported (Santos et al., 73 
2009). 74 
In wastewater treatment plants (WWTP), high variations in the inlet OMP concentrations 75 
can be found. This occurs in one installation along a period of time but especially when 76 
comparing data from different plants (Miège et al., 2009; Mussolf et al., 2009; Spongberg 77 
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and Witter, 2008; Ellis, 2006; Carballa et al., 2004). The usual influent concentrations of 78 
OMPs in WWTPs are in the range of g L-1 and ng L-1. For example, some musk 79 
fragrances, such as galaxolide (HHCB), tonalide (AHTN) or celestolide (ADBI), widely 80 
used in the formulation of cosmetic products, have been found at concentrations ranging 81 
between 0.9-16.6 g L-1 (Clara et al., 2011; Carballa et al., 2004). The anti-inflammatories 82 
IBP, naproxen (NPX) or DCF were found in a wider range, going from 12 ng L-1 to 84 g 83 
L-1 (Gómez et al., 2007; Kim et al., 2007; Nakada et al., 2006; Vieno et al., 2005). 84 
Hormones are present in sewage at the lowest concentration ranges, usually below 50 ng 85 
L-1 (Belhaj et al., 2008; Carballa et al., 2004), as expected from the low medication drug 86 
doses prescribed. 87 
1.1 Concerns of the society related to OMP emissions 88 
The growing social interest in this topic is evidenced by the increasing number of news 89 
all around the world which can be found in different mass media. Since the concentrations 90 
of OMPs in water (wastewaters, surface waters, groundwater) are extremely low, 91 
especially when compared to conventional macropollutants, the reasons for such concern 92 
are not related to their chemical impact, but to other potential problems (toxicity, 93 
bioaccumulation and estrogenicity caused to the micro and macroorganisms exposed to 94 
these emissions). Adverse effects on fishes exposed to the anti-inflammatory diclofenac 95 
at 0.5-1 g L-1 have been reported by Hoeger et al. (2005) and Triebskorn et al. (2004). 96 
Eguchi et al. (2004) studied the toxicity of different antibiotics such as erythromycin 97 
(ERY), oxytetracycline and tylosin on the green algae Selenastrum capricornutum. The 98 
endocrine disrupting effect of the estrogens 17 -estradiol (E2) and the synthetic EE2 was 99 
observed in different organisms, including fishes (Parrott and Blunt, 2005; Hirai et al., 100 
2006; Orlando et al., 2007).  101 
As a consequence, the European Union decided in 2015 to include 7 OMPs in the “Watch 102 
List” of the Water Framework Directive (WFD) to discuss the future limits of discharge 103 
of these substances, namely 3 hormones (estrone, E1, E2 and EE2) and 4 pharmaceuticals 104 
(diclofenac and the macrolide antibiotics azithromycin, clarithromycin and ERY) due to 105 
their estrogenic, toxic or antibacterial resistance potential (Table 1). The aim of this 106 
legislative measure is to monitor and gather information regarding the potential risks 107 
related to the exposure to those OMPs in the aquatic environment. 108 
Table 1. European Union legislation in terms of organic micropollutants 109 
The Swiss Federal Office for the Environment (FOEN) can be highlighted as pioneer in 110 
developing a legal framework for OMP emissions in wastewater effluents.  A new Water 111 
Protection Ordinance has been applied since 2015 in order to reduce the levels of 112 
micropollutants in their water bodies. The Swiss legislation is targeting the protection of 113 
sensitive waters and drinking water sources by limiting the OMP content in treated 114 
wastewater below 20% of the concentration present in the raw wastewater. The selection 115 
of the target OMPs has been carried out based in extensive research programmes carried 116 
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out along the Swiss territory for a number of years (www.bafu.admin.ch). As a general 117 
rule, the substances which appeared most frequently and were not removed during 118 
biological treatment were selected. Each canton in Switzerland has to select 6 of a list of 119 
12 substances for which WWTPs have to achieve removal efficiencies above 80% after 120 
upgrading to advanced treatment based on ozone or activated carbon. This list comprises 121 
the following compounds: amisulpride, carbamazepine, citalopram, clarithromycin, 122 
diclofenac, hydrochlorothiazide, metoprolol, venlafaxine, benzotriazole, candesartan, 123 
irbesartan and mecoprop. 124 
1.2 Research trends compared to state of the art  125 
In order to analyse the evolution of the scientific community focus concerning OMPs in 126 
wastewater, a bibliometric study has been carried out following the strategy: Source 127 
Scopus (Title-abstract-keywords); Search pharmaceuticals and wastewater; period from 128 
2001 to 2017. In general, the studies related to pharmaceuticals during wastewater 129 
treatment have been increasing exponentially in the last decades, moving from a limited 130 
perspective mainly oriented to the occurrence to a research with an increased level of 131 
detail and complexity, as will be demonstrated in the following paragraphs.  132 
According to the scientific background, firstly the analytical methods were developed and 133 
optimized for the measurement of OMPs concentrations in different matrixes (from 134 
milliQ water to the complex mixed liquors existing in WWTPs) with the aim of assessing 135 
their occurrence in the different compartments and streams of WWTPs (Ternes et al., 136 
2001; Buser et al., 1998; Hirsch et al., 1998; Huppert et al., 1998). These first studies 137 
reported a high variability in the removal efficiencies of OMPs in wastewater treatment 138 
using similar treatment schemes (Table 2), which was attributed to the differences in the 139 
environmental and operational conditions applied (hydraulic retention time, HRT; solid 140 
retention time, SRT, etc.). Consequently, the influence of those conditions on OMP 141 
removal was the main objective of many studies (Maeng et al., 2013; Gerrity et al., 2011). 142 
Most of efforts carried out to elucidate the behaviour of OMPs along WWTPs have 143 
focussed on the determination of the overall removal efficiencies achieved by different 144 
technologies (activated sludge, membrane reactors, postreatments, etc.) working under 145 
different operational conditions (Clara et al., 2005a; Reif et al., 2008) and only in few 146 
cases the removal mechanisms in each specific case were the subject of the research 147 
(Carballa et al., 2007; 2004; Alvarino 2014). Attention was especially paid to the sorption 148 
and/or biotransformation of OMPs. In this sense, Ternes et al. (2004) reported a rapid 149 
method to measure the solid-water distribution coefficient to determine sorption of 150 
pharmaceuticals onto sludge, whereas Joss et al. (2005) studied sorption and 151 
biotransformation of different pharmaceuticals and musk fragrances taking place in 152 
biological reactors of WWTPs.  153 
Table 2. Overall ranges for removal efficiencies reported for selected OMPs in wastewater 154 
treatment (Behera et al., 2011; Lin et al., 2010; Gómez et al., 2007; Kupper et al., 2006; Nakada et al., 155 
2006; Bester, 2005; de Mes et al., 2005; Carballa et al., 2004; Baronti el al., 2000;  Stumpf et al.,1999; 156 
Ternes et al., 1998) 157 
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Along the last years, the number of works following this approach has been increasing, 158 
with the aim of applying this knowledge to the design and development of innovative 159 
wastewater treatment technologies able to remove OMPs more efficiently. New 160 
technological approaches include hybrid reactors, the use of membranes, supports and/or 161 
adsorbents (Escolà-Casas et al., 2015; Falås et al., 2013), post-treatment with activated 162 
carbon or ozone (Kovalova et al., 2013; Margot et al., 2013), etc. These new treatment 163 
strategies are conceived for including modifications in the existing plants (not only related 164 
with their physical configuration but also their way of operation) and also for constructing 165 
new installations. In both scenarios, the formulation of a conceptual design to maximise 166 
OMPs removal requires a detailed knowledge about key mechanisms involved in their 167 
transformation, being the analysis of the processes at macroscopic level not sufficient. 168 
This was the starting point for more specific studies such as those addressing primary and 169 
secondary metabolism, metabolic pathways and even enzymatic activities. 170 
The aim of the present review is to obtain a clear picture of the main issues involved in 171 
this challenging topic, focussing on the evolution observed along the first 17 years of this 172 
century, based on an extensive bibliometric study. This period matches with the time 173 
passed from the adoption of the WFD (October 2000) up to the final inclusion of the first 174 
group of pharmaceutical OMPs in the “Watch List” (2015). Besides, the last two years 175 
2016-2017 can be an indicative of the impact of such decision. The article is structured 176 
according to the time evolution of the main topics identified in Fig. 1: i) occurrence and 177 
fate; ii) influence of operational conditions applied in WWTPs; iii) identification of 178 
removal mechanisms; iv) technological concepts addressing OMP removal and v) 179 
metabolism/cometabolism. 180 
Fig. 1 Evolution of research trends dealing with OMPs in WWTPs 181 
 182 
2. Occurrence and fate 183 
Fig 2A shows the number of publications along the period 2001-2017 for different groups 184 
of OMPs. A clear growing trend can be observed for all categories. In the case of 185 
pharmaceuticals, PCPs and BFRs, around 70% of publications were released in the last 7 186 
years. Somewhat lower values (50-60%) were found for the rest of compounds. In the 187 
case of pesticides and biocides, the relative number of publications in the period 2001-188 
2005 was already significant, indicating that the concern on those persistent organic 189 
pollutants started earlier than those related to pharmaceuticals and personal care products. 190 
The number of works containing the terms “wastewater” and the specific group of OMP 191 
were: 4663 with “pharmaceutical”, 1002 with “PCP”, 1170 with “EDC”, 1183 with 192 
“pesticide”, 320 with “biocide”, 172 with “LAS” and finally 92 “BFR” (Figure 2A). Thus, 193 
among these 7 categories, half of the scientific interest was focussed on pharmaceuticals 194 
along the entire 17 years considered. 195 
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Fig. 2 Scientific papers published along 2001-2017: A) types of OMPs in wastewater; 196 
B) selected pharmaceuticals and estrogens in wastewaters; C) fate of pharmaceuticals in 197 
wastewaters  198 
(Source: Scopus; General Search: GS; Specific Search: SS. Full spelling of terms was used in 199 
the search). 200 
Among the wide number of pharmaceuticals and EDCs reported, it is interesting to note 201 
that some specific substances are present in a growing number of articles, such as three 202 
specific pharmaceuticals (DCF, ERY and carbamazepine, CBZ) and three hormones (E1, 203 
E2, EE2), as shown in Fig. 2B. One of the factors explaining their consideration as 204 
representative OMPs is their inclusion in the European and/or Swiss legislation. 205 
According to the number of publications, those related to DCF, E2 and CBZ in wastewater 206 
represent the double compared to the other 3 compounds (around 1000 vs. 500, 207 
respectively). If their time evolution is analysed, DCF, ERY and CBZ show a stepwise 208 
increasing trend especially highlighted since 2011. In fact, around 70% of their respective 209 
publications were released in the last 7 years. In the case of ERY this trend could be 210 
related to the current concern about antimicrobial resistance derived from the discharge 211 
of antibiotics into the environment. Within the hormones, E2 received more attention 212 
compared to EE2 and E1, although EE2 has shown to be a more potent endocrine 213 
disruptor than the natural hormones with in vivo juvenile rainbow trout screening assays 214 
(Thorpe et al., 2003). For these EDCs, the interest in publication increased especially in 215 
period 2006-2010, while the figures related to the period 2011-2017 reveal a certain 216 
stabilization trend. 217 
If the bibliometric search is refined from pharmaceuticals in “wastewater” to “fate of 218 
pharmaceuticals in wastewater”, which is related to a more technological approach, the 219 
number of studies decreases in one order of magnitude, as illustrated by Fig. 2C, with 578 220 
works along the 17 years analysed. Although publications with a global perspective on 221 
the fate of pharmaceuticals in wastewater treatment are clearly the most abundant, other 222 
on more specific topics, such as the identification of the main removal mechanisms and 223 
the development of technologies targeting pharmaceutical removal have evidenced a 224 
growing trend (Fig. 2C). This is especially clear along the last two years, when the 225 
publications related to “fate” already achieved 52% of those corresponding to 2011-2015, 226 
and in the case of “removal mechanisms” an outstanding value of 111% was achieved. 227 
On the other hand, studies about the role of primary/secondary metabolism on 228 
pharmaceuticals biotransformation are very scarce, with only 6 articles found since 2006. 229 
Publications tackling the study of pharmaceutical removal mechanisms suppose a 9% of 230 
the total publications on the fate of pharmaceuticals in WWTPs, whereas only 1% deals 231 
with the primary/secondary metabolism responsible for pharmaceutical 232 
biotransformation. 233 
The geographical involvement of the scientific community in the study of the fate of 234 
pharmaceuticals in wastewater has been changing over time. In Fig. 3 the total number of 235 
publications per country origin (PCO) for each period is shown. It represents the number 236 
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of publications in which research groups from a given country were involved. The first 237 
works were concentrated in only 14 countries, with an outstanding productivity in the 238 
United States, Germany and Switzerland (Fig. 3A). In fact, the US has been leading the 239 
number of publications in all periods analysed. The number of countries involved in this 240 
research has been continuously increasing, achieving a total number of 42 in the last two 241 
years (2016-2017). China started to publish on this topic later in 2006, reaching the 242 
second position from 2011 onwards. A similar trend can be observed for Canada. Spain 243 
moved from a modest position in 2001-2005 to the top-4 in the following 12 years. Since 244 
the beginning, UK, France and Australia maintained a quite stable position in the ranking, 245 
while other countries as for example Switzerland left the topic in the last 7 years. Most 246 
probably, this was because the OMP presence in wastewaters has been incorporated into 247 
Swiss regulations moving the challenge to full-scale implementation. Besides, it is worth 248 
to note the increasing number of developing countries all around the world that have 249 
started focussing their attention on this issue in the last two years. India, Taiwan, Brazil 250 
and Pakistan are examples of this evolution.  251 
In order to identify the main research trends in the different countries, Fig. 4 shows the 252 
previous search (Fig. 2C) refined with three selected research fields: removal mechanism, 253 
technology and co-metabolism. In the first case, Fig. 4A shows that groups from 23 254 
countries have been involved in the assessment of removal mechanisms, being observed 255 
that 50% of the pie chart belongs to four countries: United States, China, Germany and 256 
Spain. In the case of technologies, Switzerland, Canada and Great Britain are also present 257 
in the first positions from a total of 29 countries involved (Fig. 4B). Few articles address 258 
the role of the cometabolic biotransformations taking place during the abatement of 259 
pharmaceuticals, belonging to research groups from the United States, followed by 260 
France, China, Spain and, more recently, Denmark (Fig. 4C). 261 
The number of collaborations between research groups from different countries working 262 
on the fate of pharmaceuticals in wastewaters can be analysed from the ratio between the 263 
sum of publications per country origin (SPCO) in Fig. 3 and the sum of publications (SP) 264 
corresponding to a certain period (Fig. 2). The ratio SPCO/SP was of 1.21, 1.34, 1.33 and 265 
1.41 going from the first (2001-2005) to the fourth (2016-2017) period considered, 266 
respectively. These numbers evidence the increasing trend in the collaborations between 267 
research groups from different countries on that topic. 268 
 269 
Fig. 3 Publications per country origin focussed on the fate of pharmaceuticals in wastewater in 270 
the period 2001-2017 classified by country (source: Scopus; GS:  pharmaceutical, wastewater, 271 
fate; SS: period; country codes according to ISO 3166) 272 
 273 
Fig. 4 Publications per country origin dealing with the different research fields focussed on fate 274 
of pharmaceuticals in wastewater in the period 2001-2017 classified by country  275 
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(source: Scopus; GS:  pharmaceutical, wastewater, fate; SS: research field;  276 
country codes according to ISO 3166) 277 
 278 
3. Influence of operational conditions 279 
There is not a unique classification of OMPs in function of their removal in WWTP due 280 
to the broad ranges of removal efficiencies reported for most of these compounds 281 
(Table 2). This different behaviour could be partially explained in terms of the different 282 
environmental and operational conditions applied in each case, such as HRT, SRT and 283 
redox conditions (Table 3). For instance, IBP is considered one of the most readily 284 
biodegradable OMPs in conventional biological treatments (Clara et al., 2005a; Carballa 285 
et al., 2004). However, IBP is a recalcitrant compound under anaerobic conditions 286 
(Alvarino et al., 2014).  287 
Table 3. Influence of SRT, HRT and temperature in the removal of OMPs (Fernandez-Fontaina et 288 
al., 2012; Reif et al., 2011; Suárez et al., 2010; Clara et al., 2005b; Tauxe-Wuersch et al.,2005) 289 
 290 
3.1 Hydraulic and sludge retention time 291 
Maurer et al. (2007) observed that the removal efficiencies of some betablockers strongly 292 
correlated with the HRT. Clara et al. (2005a) reported a high dependence of the behaviour 293 
of the anti-inflammatory DCF, with removal efficiencies around 70% at long HRTs (13 294 
d) which became negligible when a lower HRT was applied (1.2 d). Fernandez-Fontaina 295 
et al. (2012) reported an increase in the removal of ROX and FLX at higher HRTs, 296 
whereas no influence of the HRT was observed for IBP and NPX. These differences can 297 
be related to kinetic limitations, which are especially relevant in the case of the 298 
compounds with medium biodegradability.  299 
The operation at high SRT allows the increase of the microbial diversity due to the 300 
development of slowly growing bacteria, as well as higher biomass concentrations and 301 
better acclimation to disturbances and toxic substances (Clara et al., 2005b). De la Torre 302 
et al. (2015) operated an IFAS-MBR (a membrane bioreactor which combines suspended 303 
and fixed biomass) at different SRTs (10 and 20 d). Higher removal efficiencies of 304 
pharmaceuticals were observed when operating at an SRT of 20 d. Surprisingly, a removal 305 
efficiency above 80% was reported for carbamazepine in the IFAS-MBR operated at an 306 
SRT of 20 d (De la Torre et al., 2015), which was related to the operation at low F/M 307 
ratios which induced the microorganisms to biotransform the recalcitrant compounds 308 
(Verlicchi et al., 2012). Suárez et al. (2012) reported a significant influence of the SRT on 309 
the removal of lipophilic compounds, such as estrogens or musk fragrances. For instance, 310 
EE2 removal increased 11% when the SRT was maintained above 20 d. For these 311 
compounds, a stronger influence of the SRT compared to the HRT was reported, based 312 
on the assumption that compounds with a low biological kinetic constant can be 313 
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biologically transformed at high SRTs if they are mainly sorbed onto the sludge. Reif et 314 
al. (2011) compared the removal of OMPs in a MBR operated with a SRT of 6 and 20 d 315 
and observed a reduction in the discharge of acidic drugs and musk fragrances in the final 316 
effluent at the higher SRT. In fact, Clara et al. (2005b) identified that SRT > 10 d increased 317 
removals for several OMPs, such as hormones and ibuprofen. The enhancement in the 318 
removal of certain OMPs when the SRT is increased has been related to the presence of 319 
slowly growing nitrifiers (Miège et al., 2009; Göbel et al., 2007; Clara et al., 2005b), as 320 
occurs with ibuprofen, estrone or estradiol, whose removal has been correlated with the 321 
nitrification activity (Alvarino et al., 2016a). 322 
 323 
3.2 Redox conditions 324 
Redox conditions strongly influence the degree and route of OMP biotransformation. The 325 
OMP behaviour is mainly related to the chemical structure of the compound and the 326 
metabolic pathways promoted under each environment (Fig. 5 and 6).  In general, OMPs 327 
are removed to a higher extent under aerobic conditions (Alvarino et al., 2018). For 328 
instance, a recalcitrant behaviour was reported by McAvoy et al. (2002) in the case of 329 
triclosan under anaerobic conditions, while it was a readily removed in aerobic processes. 330 
However, some pharmaceuticals, like SMX or NPX, were easily removed at negative 331 
redox conditions, with removal efficiencies above 99% for SMX during the anaerobic 332 
digestion of sludge (Carballa et al., 2007a). Comparing the aerobic and anoxic removal 333 
of OMPs, it was reported that most of the compounds were efficiently removed under 334 
aerobic conditions, whereas three compounds (ROX, CLA, and clindamycin (CLI)) were 335 
removed only under anoxic conditions (Burke et al., 2014). In general, the operation of 336 
biological reactors at different redox conditions results in an increased microbial diversity 337 
and a broader enzyme spectrum which enhances OMPs biotransformation (Suárez et al., 338 
2012). 339 
Fig. 5. Biotransformable and recalcitrant moieties under anaerobic conditions  340 
 Fig. 6. Biotransformable and recalcitrant groups under aerobic conditions 341 
 342 
3.2.1 Anaerobic conditions 343 
The presence of electron-withdrawing groups enhances the removal of OMPs by 344 
reductive biotransformation reactions (Banzhaf et al., 2012; Field, 2002), whereas the 345 
cyclic or heterocyclic groups or the halogens in the chemical structure difficult the 346 
removal under anaerobic conditions (Fig. 5, Dutta et al., 2014; Monsalvo et al., 2014; 347 
Musson et al., 2010; Adrian et al., 1994), as in the case of progesterone, DCF, CBZ or 348 
DZP. The substituted heterocycles are susceptible to be degraded under anaerobic 349 
conditions (Adrian et al., 1994). This was the case in the metabolic route proposed by 350 
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Alvarino et al. (2016b) for SMX removal in a pure anaerobic culture being the attack site 351 
in the substituted heterocycle 3-amino-5-methyl-isoxazole ring. 352 
Under negative redox conditions, OMPs removal can occur by hydrogenation or 353 
hydroxylation reactions. The hydroxylation of the carbons present in the aromatic ring 354 
promotes the ring cleavage under anaerobic conditions. However, the hydroxylation can 355 
be interfered by some ring substitutions, as in the case of acetaminophen. Its low removal 356 
might be associated with the branched chain substitution in the aromatic ring (Musson et 357 
al., 2010). Carboxylic and hydroxyl functional groups promote the hydroxylation 358 
(Musson et al., 2010). For instance, metoprolol (MTP) is an OMP with a medium-high 359 
removal because its structure contains a hydroxyl moiety, in spite of the presence of an 360 
amine group that is recalcitrant under anaerobic conditions (Musson et al., 2010). 361 
Nonylphenol and the short-chain nonylphenol ethoxylates are the intermediate products 362 
of the anaerobic removal of the surfactant nonylphenol ethoxylates due to the sequential 363 
removal of ethoxyl groups (Lu et al., 2008, 2007). Falås et al. (2016) observed the 364 
demethylation and deionination of organic micropollutants with a recalcitrant behavior 365 
under aerobic conditions, such as diatrizoate or venlafaxine, in an anaerobic postreatment.  366 
 367 
3.2.2 Aerobic conditions 368 
Under aerobic conditions, Boethling et al. (1994) showed that the presence of heterocyclic 369 
N-containing aromatic rings hampers biodegradation (Fig. 6), which explains the stability 370 
of CBZ that contains three fused aromatic rings (Fernandez-Fontaina et al., 2016). The 371 
presence of chlorine atoms in the OMP structure generates an electron deficiency, thus 372 
the molecule is less susceptible to oxidative catabolism (Knackmuss, 1996; Keener and 373 
Arp, 1993). The micropollutants with electron donating functional groups, such as amines 374 
or hydroxyl groups, are more prone to be biotransformed by an electrophilic attack by 375 
oxygenase enzymes (Tadkaew et al., 2011). For instance, Müller et al. (2013) studied the 376 
biotransformation of SMX under aerobic conditions and 3-amino-5-methyl-isoxazole 377 
was the main stable metabolite detected, being the attack site in the amine. Jewell et al. 378 
(2016) observed the removal of TMP by demethylation to form the intermediate 379 
metabolite 4-desmethyl-TMP under aerobic conditions. This metabolite was not stable 380 
and quickly transformed to 2,4-diaminopyrimidine-5-carboxylic acid by hydroxylation 381 
and oxidation. Other authors showed another biotransformation pathway for TMP by 382 
ether cleavage (Quintana et al., 2005). 383 
A wide range of polycyclic aromatic hydrocarbons, aryl ethers and aromatic ethers, such 384 
as naphthalene (NAP), diphenyl ether (DE) or anisole can be cometabolically degraded 385 
through O-dealkylation or hydroxylation by the ammonia monooxygenase (AMO) 386 
enzyme, produced by ammonium oxidizing bacteria (Chang et al., 1997), as well as the 387 
straight-chain hydrocarbons through hydroxylation (Hyman et al., 1988). Tadkaew et al. 388 
(2011) showed a high removal of micropollutants with an aromatic-aliphatic ether, such 389 
as gemfibrozil (98%) and verapamil (87%), that can be biotransformed by ether cleavage.  390 
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Dorival-Garcia et al. (2013) observed a medium removal of the quinolone antibiotics (14-391 
40%) under aerobic conditions, while the biodegradation was negligible under anoxic 392 
environments. This difference can be related to the higher oxidation potential of the 393 
oxygen, compared to the nitrate (Sigg, 2000), since redox reactions occur in the order of 394 
the thermodynamic conditions, being oxygen the lowest unoccupied electron level 395 
(Stumm and Morgan, 1996). Due to that, the hydrolysis of primary and secondary amides 396 
can occur under both redox conditions, while the oxidation of tertiary amides is viable 397 
only under aerobic conditions (Helbling et al., 2010). 398 
 399 
4. Identification of the OMP main removal mechanisms 400 
Once the occurrence and fate of the OMPs are accurately determined in WWTPs, the next 401 
step consists in the understanding of the behaviour of these substances during biological 402 
treatment. Taking into account the three phases in which the OMPs can be present in a 403 
biological reactor (solid, liquid and gas streams), three main removal mechanisms can be 404 
distinguished: biotransformation, sorption, and volatilization (Pomiès et al., 2013; Joss et 405 
al., 2006). Volatilization and sorption consist in the transfer of OMPs between two 406 
compartments based on equilibrium mechanisms (liquid-gas, and liquid-solid, 407 
respectively), whereas biotransformation is the degradation of the parent OMP in the 408 
mixed liquor (Pomiès et al., 2013). In WWTPs, the fate and behaviour of OMPs strongly 409 
depend on the physicochemical properties of the compound (Boethling et al., 2007) and 410 
the type of treatment processes applied (physicochemical or biological). 411 
Volatilisation depends on the physicochemical properties of the OMPs, such as the Henry 412 
law constant (H), as well as on the conditions of the process, such as the air flow, stirring 413 
or temperature. In WWTPs, two volatilization processes can be involved: stripping and 414 
surface volatilization. In general, the contribution of the volatilization to the overall 415 
removal of OMPs is negligible. Only for some compounds, such as the musk fragrance 416 
celestolide (ADBI), volatilization has to be taken into account in the mass balances. 417 
Suárez et al. (2012), who studied the removal of musk fragrances in a single-sludge 418 
nitrification-denitrification plant, observed that around 20-40% of the removal of ADBI 419 
was due to stripping, whereas Alvarino et al. (2014) determined a low contribution of 420 
volatilization (5-15%) in a CAS unit. 421 
Sorption depends on the OMP lipophilic character or its tendency to be ionized or 422 
dissociated in aqueous phase (presence of amino or carboxyl groups, etc.), as well as on 423 
the physico-chemical characteristics of the sludge (organic compound fraction or particle 424 
size) (Verlicchi et al., 2013). Two mechanisms have to be taken into account (Sipma et 425 
al., 2010): absorption, that is associated to the hydrophobic interactions between the 426 
aliphatic and aromatic groups of a compound with the lipophilic cell membrane of the 427 
microorganisms and the fat fractions of the sludge, and adsorption, that refers to the 428 
electrostatic interactions of the positively charged groups of the OMPs with the negatively 429 
charged surfaces of the microorganisms (Verlicchi et al., 2013). The trend to be absorbed 430 
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is usually related to the octanol-water coefficient (Kow) (Suárez et al., 2008). Among 431 
OMPs characterized by a high Kow are the musk fragrances or fluoxetine (Alvarino et 432 
al., 2018; Horsing et al., 2011). In the case of the hydrophobic OMPs, the charge and the 433 
molecular size explain their adsorption into the negatively charged biomass (Wunder et 434 
al., 2011).  This fact explains the higher adsorption of ERY (positively charged) compared 435 
to the SMX (negatively charged) (Wunder et al., 2011).  436 
Biotransformation in WWTPs is related to the biochemical reactions induced by the 437 
presence of microorganisms in water, such as bacteria, which assimilate the pollutants as 438 
growth or maintenance substrates leading to their transformation (Tran et al., 2013; Yang 439 
et al., 2013). Although complete degradation (biomineralization) can be reached for some 440 
OMPs, for most of them the removal efficiencies achieved are only partial, being some 441 
compounds completely recalcitrant (Clara et al., 2004; Collado et al., 2014). The study of 442 
the metabolites generated as intermediate products is a very useful tool to understand the 443 
fate of OMPs in bioprocesses as well as the biochemical reactions and enzymes involved.  444 
As previously studied in section 3.2, the degree of OMP biotransformation under the 445 
different redox conditions applied during wastewater treatment is very much influenced 446 
by the chemical structure of the compounds. Other parameters of the biological processes 447 
that play a key role on the OMP fate, include the biomass concentration and activity 448 
(heterotrophic aerobic/anoxic/anaerobic, nitrifying), as well as the operational conditions 449 
considered (HRT, SRT). Other influencing factors less considered in literature include the 450 
bioavailability of the substance to be biotransformed or the fraction of inert matter 451 
contained in the sludge. As an overall approach biotransformation is quantified by 452 
biological kinetic coefficients (kbiol). Normally the mass balances assume pseudo steady-453 
state conditions, a continuous stirred tank reactor model pattern and pseudo-first-order 454 
kinetics (Joss et al., 2006; Ternes et al., 2006). The information obtained through this 455 
approach is interesting and very useful especially to compare the differences in 456 
biotransformation between OMPs. However, the high number of factors involved makes 457 
that kbiol only gives accurate biotransformation rates under the specific conditions studied, 458 
being difficult to extrapolate them to other configurations.  459 
The influence of biomass concentration on the value of the kinetic coefficients can be 460 
illustrated by the following case study for the anti-inflammatory NPX (Alvarino et al., 461 
2014). The kbiol coefficient was determined for this OMP in two reactors: an aerobic CAS 462 
unit and an anaerobic UASB reactor, treating the same influent. Although NPX was 463 
removed to a high extent in both systems, the calculated kbiol in the anaerobic system (1.1 464 
L gVSS
-1 d-1) was much lower than in the CAS unit (9 L gVSS
-1 d-1), being this difference 465 
related to the biomass concentration (30 and 1.8 gVSS L
-1, respectively).  466 
 467 
5. Technological concepts for OMPs removal 468 
In the case OMPs removal is aimed due to their possible toxicity and bioaccumulation 469 
potential, it should be specifically addressed when conceiving innovative processes. This 470 
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is especially relevant for wastewaters containing higher amounts of OMPs, such as 471 
hospital wastewater (HW) with concentrations of pharmaceuticals 4-150 times higher 472 
compared to those present in municipal wastewater (Verlicchi et al., 2010).  473 
Processes based on conventional activated sludge (CAS) for carbon and nutrient removal 474 
are the most extended technologies implemented in urban WWTPs. They consist of a 475 
biological reactor with suspended biomass (or a series of them) followed by a settler. 476 
Although these processes are able to readily remove certain OMPs, such as IBP, 477 
acetaminophen (PAR), acetylsalicylic acid (ASA), musk fragrances or bisphenol A 478 
(BPA), other compounds show a recalcitrant behaviour reaching the final effluents of the 479 
WWTPs and thus being discharged into the environment (Gabet-Giraud et al., 2010; Clara 480 
et al., 2005a; Carballa et al., 2004). Although there has been a huge development of 481 
innovative technologies (hybrid systems considering different redox conditions, biomass 482 
configurations, use of membranes, etc.) to address the challenges of achieving more 483 
sustainable wastewater treatment in accordance with the current regulations in developed 484 
countries (e.g. EU WFD), the removal of OMPs is usually not addressed specifically. 485 
In the case of new technological developments targeting OMPs removal, most of the 486 
publications are focussed in MBR systems (Park et al., 2017; Reif et al., 2008; Abegglen 487 
et al., 2009; Clara et al., 2005), while only few papers considered for instance the 488 
anammox-based configurations (Kassotaki et al., 2018, Laureni et al., 2016; Alvarino et 489 
al., 2015; de Graaf et al., 2011). The first works dealing with OMP removal in MBRs 490 
compared to the conventional processes were published in 2005 (Clara et al., 2005a), 491 
while the first report of a hybrid process combining the use of supports and suspended 492 
biomass can be found in 2008. Three years later, in 2011 the first results were published 493 
concerning OMPs behaviour in an anammox-based process (de Graaf et al., 2011).  494 
Among the most innovative technological options proposed for increasing OMP removal 495 
during secondary wastewater treatment, the following features can be summarised: i) the 496 
use of reactors operating at high biomass concentrations and long SRTs; ii) the use of 497 
different biomass conformations (biofilms, granular, flocculent); iii) the combination of 498 
several redox potentials; iv) the promotion of more specific bacterial populations  and v) 499 
the addition of adsorbents directly into the mixed liquor of biological reactors. The 500 
innovative systems considered in this paper are based on the combination of these new 501 
technological options. 502 
 503 
5.1 Technologies promoting higher biomass retention 504 
5.1.1 Membrane bioreactors (MBRs) 505 
MBRs are particularly relevant when available space is a serious limitation and water 506 
reclamation is an important issue. This technology has some advantages compared to the 507 
CAS process, such as the high-quality effluents produced, the low sludge production and 508 
the possibility to work at short HRTs (Ng et al., 2007; Stephenson et al., 2000). 509 
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Additionally, the use of membranes allows increasing the sludge concentration and the 510 
SRT applied so that the biomass growth is not restricted to the fast-growing and floc-511 
forming microorganisms (Radjenović et al., 2009; Brepols et al., 2008).  512 
Better OMP removal efficiencies in MBR compared to CAS units have been reported in 513 
different works (Radjenović et al., 2009; González et al., 2006; Kimura et al., 2005; 514 
Quintana et al., 2005). The particular operational conditions of MBRs have shown to 515 
enhance the removal of OMPs by sorption, such as in the case of tetracycline, 516 
ciprofloxacin (CIP) or ofloxacin (OFL), as well as by biotransformation due to the 517 
development of slower growing species (de la Torre et al., 2015; Kim et al., 2007). The 518 
consequent reduction of the F/M ratio could benefit biotransformation of the more 519 
recalcitrant compounds (De Wever et al., 2007; Clara et al., 2005a). Other authors showed 520 
comparable results in MBR and CAS systems if similar operational conditions were 521 
applied (Clara et al., 2005a; Joss et al., 2005). Reif et al. (2011) determined higher OMP 522 
removals in an MBR compared to a CAS when the SRT was 10 d, whereas the differences 523 
were not significant anymore when both systems were operated with an SRT of 20 d.  524 
The role of OMP retention by the membrane due to size exclusion is only relevant in the 525 
case of nanofiltration or reverse osmosis. Xue et al. (2010) reported a removal of OMPs 526 
by sorption into the membrane body and/or on the cake layer. Even OMP retention by 527 
size exclusion in the cake layer has been observed (Terzic et al., 2005). Membranes 528 
produced with hydrophobic materials have shown significant sorption of OMPs (Jermann 529 
et al., 2009).  530 
 531 
5.1.2 Biofilm reactors 532 
Among the biofilm reactor concept, some alternatives combine suspended and attached 533 
biomass, allowing the achievement of high biomass concentrations and SRT compared to 534 
CAS systems. The use of supports allows the development of a broader spectrum of 535 
microorganisms that could be active in the biotransformation of some OMPs, due to the 536 
retention in the system of slow-growing bacteria. This is the case of nitrifiers that were 537 
promoted by the use of supports (Di Trapani et al., 2014). Falås et al. (2012) observed a 538 
higher removal rate per unit biomass in a biofilm compared to the suspended biomass for 539 
DCF, KET, mefenamic acid, gemfibrozil and clofibric acid. The formation of anoxic and 540 
anaerobic environments inside the biofilm promoted biotransformation routes under 541 
different redox conditions (Alvarino et al., 2017).  542 
High removal efficiencies (> 80%) were achieved in moving bed MBRs (MBMBR)  for 543 
IBP, NPX or ASA, mainly related to the presence of strong electron donating functional 544 
groups, such as hydroxyl groups, which enhance the removal of OMPs under aerobic 545 
conditions (Luo et al., 2014). This high removal could be related to the ability of the 546 
ammonia oxidizing bacteria to oxidize compounds with hydroxyl groups (Fernandez-547 
Fontaina et al., 2012).  548 
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De la Torre et al. (2015) assessed the removal of OMPs in different reactors operating 549 
with suspended and attached biomasses. The best behaviour in terms of OMPs removal 550 
was achieved in the IFAS-MBR with average removal efficiencies above 65% due to the 551 
combination of both types of biomasses in high concentrations. On the other hand, low 552 
removals were observed in the system operated only with attached biomass due to the 553 
low biomass concentrations. Arya et al. (2016) reported that a submerged attached 554 
biofilter (SABF) was the most effective and robust system to remove OMPs compared to 555 
a MBR and a CAS unit, although only slight differences in the effectiveness were 556 
observed between the MBR and the SABF. 557 
 558 
5.2 Combination of different redox conditions 559 
One of the trends in the development of innovative WWTP configurations is the 560 
application of different redox potentials to enhance the microbial diversity. The aim is to 561 
biotransform a wider range of complex pollutants while maintaining a high degree in the 562 
COD and nutrient removal processes (Luo et al., 2014). Aerobic processes are still the 563 
most applied in secondary wastewater treatment, despite of their energetic inefficiency. 564 
Aeration consumes around 40% of the total electric energy (McCarty et al., 2011), being 565 
45 % of the total COD in the raw wastewater lost as carbon dioxide (Guo et al., 2010). A 566 
more sustainable alternative consists of applying methanogenic anaerobic digestion, 567 
which enables the recovery of energy in the form of biogas (Silvestre et al., 2015), with 568 
the consequent reduction in the net energy consumption (Dai et al., 2015). This justifies 569 
the progressive installation of new anaerobic methanogenic reactors in the water line 570 
followed by aerobic post-treatment steps, in order to promote the valorization of the 571 
organic matter contained in wastewaters (Bustillo-Lecompte et al., 2017; Lv et al., 2017; 572 
Buntner et al., 2011). The combination of the three redox potentials (anaerobic-anoxic-573 
aerobic) allows achieving complete removal of nutrients, such as nitrogen and 574 
phosphorous (Zhang et al., 2016; Liu et al., 2013). 575 
 576 
5.2.1 Methanogenic anaerobic steps 577 
Most of the available information about the removal of OMPs under anaerobic conditions 578 
refers to the sludge line. The application of anaerobic conditions has shown to be positive 579 
for the removal of some OMPs, as TMP, SMX and KET, when wastewater is treated in 580 
an anaerobic MBR (Monsalvo et al., 2014). Several OMPs, such as diuron, DCF or TMP, 581 
require an anaerobic treatment to be biotransformed (Falås et al., 2016).  In the case of 582 
the hormones E1, E2 and EE2, higher removals were reported under aerobic conditions 583 
compared to the results obtained under negative redox potentials in the water line (Zhang 584 
et al., 2015; Joss et al., 2004). 585 
Alvarino et al. (2016) has studied the removal of OMPs in an methanogenic anaerobic 586 
reactor followed by an aerobic MBR post-treatment (anaerobic hybrid MBR process). 587 
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Biotransformation of OMPs prone to be removed under anaerobic conditions was 588 
reported (e.g. TMP or SMX), although most of the OMPs were mainly removed under 589 
aerobic conditions. 590 
 591 
5.2.2 Non methanogenic anaerobic steps 592 
Processes based on MBRs comprising different redox conditions (anaerobic, anoxic and 593 
aerobic) for carbon and nutrient removal have gained interest (Silva-Teira et al., 2017; 594 
Leyva-Díaz et al., 2016; Hu et al., 2014). In these systems, the internal recirculation (IR) 595 
ratio is one of the key operational factors for process optimisation. Phan et al. (2014) 596 
studied the removal of 30 OMPs, analyzing the IR rate between the aerobic and the anoxic 597 
stages in an anaerobic-anoxic-aerobic process. The supply of nitrate, as well as the 598 
dilution, mass transfer and the microaeration in the anoxic chamber are a function of the 599 
internal recirculation rate. For 9 OMPs evaluated, such as triclosan, o-nonylphenol (NP) 600 
or 17b-estradiol-17-acetate, removals above 50% were obtained under anaerobic and 601 
anoxic conditions without any influence of the IR rate. Negligible removal was observed 602 
under anaerobic conditions for 11 OMPs, such as KET, IBP, ASA or formononetin, which 603 
were biotransformed to a moderate extent under anoxic conditions. Suárez et al. (2012) 604 
studied the effect of the IR in a denitrification-nitrification single sludge unit and reported 605 
an improvement in the removal of IBP, NPX, CTL and FLX when the IR to the anoxic 606 
stage was increased. The enhancement was related to a more effective mixing and the 607 
transport of oxygen from the aerobic to the anoxic chamber. Xue et al. (2010) studied the 608 
removal of 19 OMPs in an anaerobic-anoxic-aerobic MBR process and observed a higher 609 
OMP elimination in the anaerobic compartment which was linked to several aspects: the 610 
rapid adsorption of OMP onto the sludge, the internal recirculation and the presence of 611 
readily biotransformable OMPs under anaerobic conditions. 612 
 613 
5.2.3 Autotrophic nitrogen removal systems 614 
One of the alternatives to conventional nitrification-denitrification is the autotrophic 615 
nitrogen removal process due to several advantages: i) lower energy consumption (less 616 
aeration is needed), ii) no need of external organic matter addition, iii) lower sludge 617 
production and, iv) lower greenhouse gases emissions (N2O, NO and less CO2 stripped) 618 
(Vázquez-Padín et al., 2014; Kartal et al., 2013, 2008; Okabe et al., 2011; Kuenen, 2008; 619 
Ruiz et al., 2006). De Graaf et al. (2011) studied the removal of several OMPs in a partial 620 
nitrification-anammox process, observing that IBP was mainly transformed in the 621 
anammox process (77%), whereas Falås et al. (2012), following IBP in kinetic batch 622 
experiments stated a clear effect of nitrification on its removal. Alvarino et al. (2015) 623 
correlated the removal of IBP with the nitritation rate in a nitration-anammox process, 624 
whereas no influence of the anammox activity was observed. In the case of the other anti-625 
inflammatories, such as KTP, NPX or DCF, low removal in an anammox process was 626 
reported by Falas et al. (2012). The anammox activity exerts a positive influence on the 627 
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removal of the antibiotic ERY, being a correlation with the nitrite removal rate reported 628 
by Alvarino et al. (2015). A low removal of DCF has been also reported by de Graaf et al. 629 
(2011), with efficiencies below 40% in a nitritation-anammox process. This behavior is 630 
similar to what has been obtained for DCF in a conventional nitrification-denitrification 631 
unit (Suárez et al., 2010). The recalcitrant behavior of CBZ and DZP has been consistently 632 
reported for the autotrophic and the heterotrophic biological nitrogen removal processes 633 
(Fernandez-Fontaina et al., 2012; de Graaf et al., 2011; Suárez et al., 2010).   634 
 635 
5.3 The use of adsorbents in biological reactors 636 
Sorption onto granular activated carbon (GAC) has been used conventionally as post-637 
treatment in order to enhance the removal of OMPs after the biological processes (Nguyen 638 
et al., 2012). Although these systems are primarily based on the physico-chemical 639 
adsorption of the target pollutants, biotransformation can also occur as a result of the 640 
development of a biofilm layer on the GAC particles (Paredes et al., 2016; Matamoros et 641 
al., 2007). Another strategy consists on the simultaneous promotion of both, 642 
physicochemical and biological processes, inside one single reactor. In this sense, Sirotkin 643 
et al. (2001) proposed a direct dosing of powdered activated carbon (PAC) into a MBR. 644 
This has shown a number of positive effects: i) reduction of membrane fouling (Alvarino 645 
et al., 2017); ii) higher removal of conventional pollutants derived from the growth of a 646 
biofilm onto the activated carbon particles (Remy et al., 2009; Rice and Robson, 1982); 647 
iii) decrease of toxicity caused by certain inhibitors on the nitrification process (Widjaja 648 
et al., 2004), and iv) retention of the PAC by the membrane. This direct addition of PAC 649 
also showed promising results for OMPs, since high removal efficiencies for the 650 
recalcitrant compounds CBZ and DZP were achieved in a sequential batch reactor (SBR) 651 
coupled to a membrane filtration tank by Serrano et al. (2011). In such systems, the OMPs 652 
are removed either by biotransformation (promoted by the suspended biomass and the 653 
biofilm) or by sorption onto the sludge and the PAC. Alvarino et al. (2016c) determined 654 
an enhancement of the OMP biotransformations after the direct addition of PAC in an 655 
MBR, which was specially relevant for the compounds with moderate biodegradability. 656 
 657 
6. Metabolism/cometabolism 658 
The OMPs are present in municipal wastewaters at much lower concentrations than the 659 
macropollutants (i.e. organic matter and nutrients). Thus, it is expected that a primary 660 
substrate is necessary for inducing the enzymes for the OMP biotransformation by means 661 
of cometabolism. During this process, the persistent compounds are converted into more 662 
biotransformable intermediate products within the global metabolic pathways (Yi and 663 
Harper, 2007).  664 
In the case of nitrification, several authors reported a simultaneous elimination of 665 
ammonia and OMPs, like EE2, IBP, NPX or trichloroethylene (TCE) (Fernandez-666 
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Fontaina et al., 2012, Yi and Harper et al., 2007; Yi et al., 2006), through cometabolic 667 
biotransformations carried out by autotrophic aerobic bacteria. The ammonia 668 
monooxygenase produced by ammonium oxidizing bacteria can easily oxidize straight-669 
chain hydrocarbons through hydroxylation (Hyman et al., 1988). Fernandez-Fontaina et 670 
al. (2016) reported a high removal of IBP and NPX under nitritation conditions due to the 671 
existence of secondary and tertiary carbons in the linear alkyl chains of these compounds, 672 
which are easy targets for nucleophilic attack by the AMO enzyme (Fig. 6). Yi and Harper 673 
(2007) reported a correlation between nitrification and the removal of the hormone EE2. 674 
They showed that the single aromatic ring of EE2 is the site of electrophilic initiating 675 
reactions because the frontier electron density of this carbon ring unit is higher than in 676 
the case of the other rings and that the pi electrons associated with this ring are sterically 677 
unhindered. Therefore, the ring cleavage was observed first in the aromatic ring of the 678 
hydroxylated EE2. In presence of the Sphingobacterium sp., Haiyan et al. (2007) 679 
proposed another metabolic route, where EE2 is initially oxidized to E1. This pathway 680 
continues with the ring cleavage of the ring B, leaving the aromatic ring initially intact. 681 
The presence of an external carbon source can lead to an enhancement in the removal of 682 
several OMPs, evidencing cometabolism for heterotrophic bacteria. Majewski et al. 683 
(2011) determined faster OMP removal efficiencies in the presence of a high number of 684 
active heterotrophs when a low SRT was applied. In the case of the antibiotic SMX, a 685 
clear positive effect on its removal under aerobic conditions was reported when an 686 
external biodegradable carbon source was added to the reactor with the aim of providing 687 
enough energy for biomass growth (Fernandez-Fontaina et al., 2016; Müller et al., 2013). 688 
The presence of heterocycles and amines, as well as the lack of alkyl side chains, hampers 689 
the biotransformation of SMX by the AMO enzyme (Boethling et al.,1994). 690 
The positive effect of the presence of heterotrophs was also demonstrated by Larcher and 691 
Yargeau (2013) for EE2 biotransformation, for which medium-high removal efficiencies 692 
were determined when using several heterotrophic pure cultures (B. subtilis, P. 693 
aeruginosa, P. putida, R. equi, R. erythropolis, R. rhodochrous, R. zopfii). In the case of 694 
the pure culture R. rhodochrous even a total removal was achieved. Other studies on the 695 
synthetic hormone EE2 reported its biotransformation by both, heterotrophic and 696 
autotrophic bacteria (Larcher and Yargeau, 2013; Khunjar et al., 2011; Yi and Harper, 697 
2007).  698 
Fernandez-Fontaina et al. (2016) applied two cosubstrates alternatively (ammonium or 699 
organic matter) in order to determine their cometabolic effect on the removal of a selected 700 
group of OMPs, observing efficient removals (> 80%) of the antibiotics ERY and ROX 701 
independently of the cosubstrate used. Tran et al. (2009) studied the cometabolic removal 702 
of OMPs by the addition of several growth substrates (ammonium and organic substrates). 703 
It was observed that for most of the OMPs higher removal efficiencies were obtained by 704 
the use of growth substrates due to the induction of the activity of the specific enzymes 705 
involved in each process. These authors identified a cometabolic biotransformation of 706 
IBP (> 75%) and to a less extent of NPX, DCF, KET, fenoprofen (FEN) or gemfibrozil 707 
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(GEM), by the heterotrophic bacteria when a nitrification inhibitor (allylthiourea) was 708 
added.  709 
Information about the OMP cometabolism under anaerobic conditions is scarce. 710 
Gonzalez-Gil et al. (2017) studied the cometabolic biotransformation of 20 OMPs during 711 
methanogenesis. The process key enzyme acetate kinase has shown to be able to 712 
biotransform OMPs that contain a carboxyl or hydroxyl group and have moderate steric 713 
hindrances, such as naproxen, nonylphenol, octylphenol or bisphenol A. 714 
In the case of primary metabolism, the presence of the OMPs in sufficient concentrations 715 
is necessary for allowing the growth and maintenance of the sludge, as well as for the 716 
production of the enzymes and cofactors responsible for the OMP biotransformations 717 
(Tran et al., 2013). Müller et al. (2013) studied the biotransformation of SMX under 718 
aerobic conditions (50 mg L-1) and determined that the sludge communities were able to 719 
use SMX both as energy supply and for growth support. More concretely, heterotrophic 720 
bacteria assimilated SMX as a carbon source, while autotrophic bacteria used SMX as N 721 
source. Other authors assessed the OMP biotransformations when being the sole available 722 
carbon source in pure cultures. For instance, Sphingomonas Ibu-2 was capable of 723 
biotransforming IBP by metabolism (Murdoch and Hay, 2005), while Pseudomonas 724 
aeruginosa TJ1 and Novosphingobium JEM-1 were able to oxidize E2 (Iasur-Kruh et al., 725 
2011; Zeng et al., 2009). 726 
 727 
Conclusions  728 
The interest of the scientific community on OMPs in wastewater in the last 17 years 729 
clearly focused on pharmaceuticals compared to other groups such as pesticides, PCPs or 730 
EDCs. The studies on the fate of these compounds has been increasing significantly 731 
according to the bibliometric study provided in this paper, moving from 38 scientific 732 
papers written by groups belonging to 14 countries in the period 2001-05 up to 264 733 
articles by groups from 44 countries in 2011-15. Only in the last two years, 2016-2017, 734 
138 articles were published by groups from 42 countries, with an increasing participation 735 
of developing countries all over the world. Not only the number of countries working on 736 
these issues has been increasing, but also the number of collaborations between research 737 
groups from different countries. As a result of this effort, the first regulations have 738 
recently started to appear (Switzerland) or are under discussion (USA, EU zone).  739 
The trend in the study of OMPs during the secondary treatment of sewage has been 740 
moving from a general overview on the fate, to more specific works that analyse the 741 
contribution of different mechanisms on the OMP removal efficiencies. There is enough 742 
information available in bibliography in order to confirm the influence of different 743 
operational parameters on the removal of OMPs. This includes HRT, SRT and redox 744 
conditions as most frequently studied parameters, but other aspects as the biomass 745 
concentration and activity play also an important role on the results achieved.     746 
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In the last years, new advanced wastewater treatment technologies have been developed 747 
in order to achieve more sustainable processes using a holistic approach. Although OMPs 748 
removal has not been usually present in these considerations, the situation is changing as 749 
new processes are already featuring enhanced OMPs removals. In the last 17 years the 750 
11% of publications on the fate of pharmaceuticals in wastewater tackled specifically 751 
technological aspects. Currently most of these works still focus on the differences 752 
between CAS and MBRs.  753 
OMPs are normally removed by cometabolism due to their low concentrations in 754 
municipal wastewaters compared to macropollutants. This implies that the metabolic 755 
route for OMPs biotransformation is a function of the primary metabolic activity and the 756 
microbial diversity, besides the other operational conditions. Still very few studies have 757 
provided insights on these relations.  758 
This review clearly demonstrates that pharmaceuticals in wastewater constitute a hot 759 
topic all around the world. An outstanding progress has been made since 2000 in 760 
determining the fate and main removal mechanisms of these compounds during 761 
wastewater treatment. However there are still important knowledge gaps that should be 762 
further studied in order to reach the desirable removal efficiencies during secondary 763 
wastewater treatments. The new technological options developed to achieve better results 764 
in terms of OMP removal should consider, besides working under different redox 765 
conditions, other factors such as the use of different biomass conformations and/or the 766 
addition of adsorbents into biological reactors. More information is needed about the 767 
cometabolic biotransformations of OMPs, since this would allow to adapt the primary 768 
metabolism to conditions favourable to the removal of these substances.  769 
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